MetaCap

REGENXBIO Inc. (RGNX)

NASDAQ: RGNXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

7.16-0.02 (-0.28%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

RGNX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$473.44M
EPS (TTM)
-$3.20
52-week range
5.46 – 16.19
Day range
6.86 – 7.30
Volume / Avg
1.05M / 1.39M
Beta
—

52-week range

$5.46$16.19

RGNX stock today

REGENXBIO (RGNX) closed at $7.16 on Nov 20, down 0.28% (-$0.02), versus the S&P 500's 3.70% decline. Shares are 55.8% below their 52-week high of $16.19, set on Jan 22, 2026 and 31.3% above the 52-week low of $5.46, near the bottom of the past year's range. RGNX is down 50.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 39.3%.

REGENXBIO has posted a net loss over the last twelve months (EPS of -$3.20), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About REGENXBIO

Company profile

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Curran M. Simpson M.S.
Headquarters
Rockville, MD
Employees
371
IPO year
2015

Financial highlights

Full financials

In fiscal 2025, REGENXBIO generated $170.4 million in revenue, up 104.5% from fiscal 2024. REGENXBIO reported a net loss of $193.9 million, compared with a loss of $227.1 million a year earlier. Operating margin was -94.6%.

REGENXBIO annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$170.44M$83.33M$90.24M$112.72M$470.35M
Growth+104.54%-7.66%-19.94%-76.03%+204.30%
Net income$-193.88M$-227.10M$-263.49M$-280.32M$127.84M
EPS (diluted)$-3.76$-4.59$-6.02$-6.50$2.91

Analyst forecast

Forecast

Consensus (11 analysts)

strong_buy

Avg. price target

$21.40+198.88%

  • Strong buy 3
  • Buy 7
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $12.00High $42.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.62 vs $-1.35
Surprise
+54.07%

RGNX news

All RGNX news

REGENXBIO peers

Health Care sector
RGNX peer companies
CompanyPrice% ChgMarket capCompare
SANASana Biotechnology Inc.1.59-8.62%$476.42Mvs RGNX
DNAGinkgo Bioworks Holdings Inc. Class A7.46-9.02%$483.54Mvs RGNX
FENCFennec Pharmaceuticals Inc.13.09-2.68%$462.14Mvs RGNX
VALNValneva SE ADR5.16-3.82%$490.86Mvs RGNX
ETRAElectra Therapeutics Inc.8.11-9.28%$509.85Mvs RGNX
IRLAIRulya Therapeutics Inc.39.88-0.15%$432.36Mvs RGNX
PROKProKidney Corp. Class A1.04-1.89%$415.21Mvs RGNX
TECXTectonic Therapeutic Inc.20.73-1.47%$405.26Mvs RGNX

Indexes, lists and sector

REGENXBIO stock FAQ

What is REGENXBIO's stock price today?

RGNX last traded at $7.16 as of Nov 20, 4:00 PM EST, down 0.28% on the day. Prices are delayed at least 15 minutes.

Who is REGENXBIO's CEO?

Mr. Curran M. Simpson M.S. is the chief executive officer of REGENXBIO Inc., which has about 371 employees.

What is the RGNX 52-week high?

The 52-week high for RGNX is $16.19 and the 52-week low is $5.46. The stock is currently 55.8% below its high.

Compare RGNX